Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC

The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Florez (DUMA), Narjust, Mcdonald, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184836/
https://www.ncbi.nlm.nih.gov/pubmed/37197732
http://dx.doi.org/10.6004/jadpro.2023.14.3.12
_version_ 1785042220252921856
author Florez (DUMA), Narjust
Mcdonald, Stephanie
author_facet Florez (DUMA), Narjust
Mcdonald, Stephanie
author_sort Florez (DUMA), Narjust
collection PubMed
description The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targeted therapies, and best practices for monitoring and managing side effects associated with targeted therapies for metastatic non–small cell lung cancer.
format Online
Article
Text
id pubmed-10184836
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-101848362023-05-16 Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC Florez (DUMA), Narjust Mcdonald, Stephanie J Adv Pract Oncol Meeting Reports The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targeted therapies, and best practices for monitoring and managing side effects associated with targeted therapies for metastatic non–small cell lung cancer. Harborside Press LLC 2023-04 2023-04-01 /pmc/articles/PMC10184836/ /pubmed/37197732 http://dx.doi.org/10.6004/jadpro.2023.14.3.12 Text en © 2023 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Florez (DUMA), Narjust
Mcdonald, Stephanie
Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
title Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
title_full Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
title_fullStr Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
title_full_unstemmed Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
title_short Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
title_sort updating the targeted therapy paradigm for patients with metastatic nsclc
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184836/
https://www.ncbi.nlm.nih.gov/pubmed/37197732
http://dx.doi.org/10.6004/jadpro.2023.14.3.12
work_keys_str_mv AT florezdumanarjust updatingthetargetedtherapyparadigmforpatientswithmetastaticnsclc
AT mcdonaldstephanie updatingthetargetedtherapyparadigmforpatientswithmetastaticnsclc

Ejemplares similares